Europe, Dr Howard Levin, President Ceo discussed on MedTech Talk Podcast
But not to do too many number on that. But you know, again, I think there's a a number of data points that. That they're strong similarity both end strategy as well as technology. Interesting. And finally, your president CEO of a both renal garden and reprieve. How do you manage the two companies at the same time or the two efforts at the Santana, you how do you view this organization how they work together to you make sure both deep on track is it has challenging as as it might appear. Not you know, not necessarily. I mean, it's it's it's you know, had it's been a a dual role really since the day. I got here and heart failure. As I said, Tom was was number one. The list understand how are proprietary technology could transfer over end liver really formidable benefits to the heart failure patients that they've not received previous. And so it's it's it's a titles names things. I don't get mixed up in that. It's just know priority businesses that we out really directed. A majority of overlap in terms of our employee base. You know, part of what we've done in in. Developing launching reprieve, obviously with Dr Howard Levin's addition to be our chief medical officer and Howard being a heart failure cardiologists by trade is is set a a key asset we've made some also some he hires in Europe and terms of both commercially driving the rental guard business as well as clinically bribing the reprieve cardiovascular business, so you know, the businesses are separate in terms of focus. But again, I go back to the Helmand fluid management platform. And also if you look at how those businesses businesses are intertwined were very fortunate time to do the clinical work that we are right now with reprieve cardiovascular in Europe, all under our currency seamark all on our current label. So as you take a look and understand reprieve. You know it. Yes, it's a startup. And were were, you know, moving vigorously to develop a very innovative therapy to provide controllable. Decongestions therapy for patients, but we've been afforded a real a real benefit in the sense that it's all under current regulatory label in Europe as well as from a manufacturing scale standpoint, you know, with twenty thousand patients on the renal guard side, you can imagine the manufacturing expertise as well. As a safety profile about side of the business that relates directly transferable to. Developing and then iterating on the harshly or technology. So Jim what is the current situation? Now are these patients handled in how will reprieve improve on it gets on the Achille to compensated heart failure population is massive in a market opportunity exceeds certainly has a billion at the end of the at least a couple billion dollars in really in terms of the of therapy care a right now or the spectrum of care, you know, patients are admitted whether it be chronic or acute and then the goal is decongestion in really the only means of decongestion right now, come in a frontline therapy mode is direct therapy. And and direct therapy has simply given to the patient. And and basically makes the patient Pete and by urine production trying to decongest that patient, and and decreasing vascular volume. Dire. Dire. Arctic therapy was invented nineteen sixty two so to think of it as as anything being cutting edge. It it's helpful. It's useful. By the way. A lot of great things were graded nineteen sixty two. I won't I won't go down that road. But. Take a look at the aftermath of care and so patients the frequent flyers. They're in the hospital five six seven eight times a year be decongested and diuretics again are can be effective. But it's there's a lot of variability and unpredictability based on dotion dosage in timing. And if the patient is going to be is going to react. And and and and the deacon Justice some extent, and it was really cautioned, and and is very conservative in dosing diorite because they certainly don't want the patient to become dehydrated because you know, bad things happen in terms of dehydration, hypertension, and eventually end organ and renal renal failure or renal harm can occur. So the vision with reprieve is that our expertise in fluid management. You know, we can ensure we're developing system with diagnostic sensors integrated..